Bank Of America Corp Sigilon Therapeutics, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $1.38 $5 - $23	-17 Reduced 0.19%	8,872 $8,000
Q4 2022 Feb 10, 2023	SELL	$0.29 - $0.69 $44 - $105	-153 Reduced 1.69%	8,889 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $327 - $587	-683 Reduced 7.02%	9,042 $5,000
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $7,189 - $15,932	-9,715 Reduced 49.97%	9,725 $8,000
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $8,494 - $20,755	-6,850 Reduced 26.06%	19,440 $29,000
Q4 2021 Feb 08, 2022	BUY	$2.58 - $6.13 $13,717 - $32,593	5,317 Added 25.35%	26,290 $72,000
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $36,133 - $86,736	8,175 Added 63.88%	20,973 $118,000
Q2 2021 Sep 13, 2021	BUY	$9.15 - $20.17 $117,101 - $258,135	12,798 New	12,798 $137,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.